HIV often shows no symptoms in the initial stages, which means individuals will unknowingly spread the virus to others and start treatment early.
World AIDS Day 2024: Molecular tests play a significant role in managing HIV infections. These tests offer detailed insights into how well the virus is controlled and the individual's immune response to the anti-retroviral therapy (ART).
Commonly used tests for HIV monitoring are:
HIV viral load testing
HIV drug resistance test
Early Detection Of Infection
Testing during Window period: Antibody may take some time to generate as it requires the host immune response to generate the anti-HIV antibodies post-exposure to HIV antigen. Serological tests, such as antibody-based tests that detect antibodies against HIV in the body, may be harmful in this initial window period. Thus, such traditional antibody-based tests may fail to detect HIV infection in the early stages (window period). In contrast, molecular tests which detect RNA or proviral DNA may detect HIV much earlier, even in the window period, after 48 hours to 7 days of the virus's entry into the human body.
HIV RNA testing: HIV RNA tests can often be detected within days to weeks, even before the antibodies appear in the patient's body, thus allowing for earlier diagnosis and initiation.
Monitoring of HIV response to therapy: The HIV viral load test (HIV quantitative PCR test) is a molecular test that detects the amount of HIV RNA copies per ml of a patient's blood plasma. This test helps determine the initial viral load basis of the HIV RNA copies, which forms a baseline before the start of treatment and later monitors the progression.
Tracking the disease progression: A high HIV viral load is associated with faster disease progression and risk of opportunistic infections due to other bacterial, fungal, or parasitic infections due to a reduced cell-mediated immune response, thus lowering immunity. Therefore, this test helps track disease progression and how well the antiretroviral therapy works. In ideal situations, potent antiretroviral drugs lower the viral load to undetectable levels, referred to as undetectable = untransmissible (U=U).
Detection of treatment failure: If the viral load does not reduce significantly, it may suggest either treatment failure, the emergence of antiviral drug resistance, or non-adherence to the regimen.
HIV resistance testing: As HIV is known to replicate in large numbers in human cells very rapidly, it leads to a high rate of mutations in its genetics. Such mutations, in turn, can lead to resistance to antiretroviral drugs used for HIV treatment, leading to treatment failure. Molecular diagnostic techniques such as HIV genotyping or genotypic drug resistance testing are used to identify mutations in the HIV genome that confer resistance to individual drugs used in HIV treatment.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
